How does HBCO's PS Ratio compare to its peers?

HBCO is good value based on its Price-To-Sales Ratio (8.1x) compared to the peer average (20.7x).

How does HBCO's PS Ratio compare vs other companies in the GB Biotechs Industry?

HBCO is good value based on its Price-To-Sales Ratio (8.1x) compared to the UK Biotechs industry average (17.2x).

What is HBCO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate HBCO's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of HBCO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate HBCO's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

HBCO Stock Overview

Operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. More details

HBCO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 15.6% per year over past 5 years

Shares are highly illiquid

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Hofseth BioCare ASA Competitors

Tissue Regenix Group

AIM:TRX

UK£42.4m

Bioventix

AIM:BVXP

UK£173.6m

Avacta Group

AIM:AVCT

UK£173.8m

Arecor Therapeutics

AIM:AREC

UK£26.2m

Price History & Performance

Summary of share price highs, lows and changes for Hofseth BioCare
Historical stock prices
Current Share Price	NOK 2.70
52 Week High	NOK 2.70
52 Week Low	NOK 2.70
Beta	0.62
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-71.82%
5 Year Change	18.94%
Change since IPO	44.39%

Recent updates

Shareholder Returns

	HBCO	GB Biotechs	GB Market
7D	0%	-4.2%	-2.6%
1Y	n/a	-24.5%	2.4%

Return vs Industry: Insufficient data to determine how HBCO performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how HBCO performed against the UK Market.

Price Volatility

Is HBCO's price volatile compared to industry and market?
HBCO volatility
HBCO Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: HBCO has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HBCO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	60	Jon Odegard	www.hofsethbiocare.com

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Hofseth BioCare ASA Fundamentals Summary

How do Hofseth BioCare's earnings and revenue compare to its market cap?
HBCO fundamental statistics
Market cap	NOK 1.09b
Earnings (TTM)	-NOK 139.56m
Revenue (TTM)	NOK 134.43m

8.1x

P/S Ratio

-7.8x

P/E Ratio

Is HBCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HBCO income statement (TTM)
Revenue	NOK 134.43m
Cost of Revenue	NOK 121.71m
Gross Profit	NOK 12.72m
Other Expenses	NOK 152.28m
Earnings	-NOK 139.56m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 25, 2023

Earnings per share (EPS)	-0.35
Gross Margin	9.46%
Net Profit Margin	-103.81%
Debt/Equity Ratio	89.7%

How did HBCO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/27 23:01
End of Day Share Price	2023/03/30 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hofseth BioCare ASA is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonas Peciulis	Norne Securities AS
Henning Steffenrud	Swedbank Norway